# Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies

> **NCT00642031** · PHASE1 · COMPLETED · sponsor: **Prescient Therapeutics, Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Hematologic Malignancies
- Leukemia

## Interventions

- **DRUG:** Triciribine

## Key facts

- **NCT ID:** NCT00642031
- **Lead sponsor:** Prescient Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642031, "Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00642031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*